SAN DIEGO-- Rempex Pharmaceuticals, Inc. today announced that it will present data describing the antimicrobial activity and preclinical safety of Carbavance, a broad-spectrum antibiotic combination agent designed to treat serious bacterial infections due to Gram-negative bacteria. Preclinical studies show that Carbavance has activity against key Gram-negative pathogens, including E. coli, Klebsiella sp., Acinetobacter sp., and Pseudomonas aeruginosa. Results from a number of these preclinical studies will be presented in 11 posters at ICAAC (www.icaac.org) on Monday, September 10.
Carbavance is a combination of a carbapenem antibiotic (RPX2003) combined with a second drug (RPX7009) that acts as an inhibitor of bacterial beta-lactamases. Beta-lactamase inhibitors are agents that inhibit bacterial enzymes that destroy beta-lactam antibiotics and result in resistance. Many Gram-negative bacteria produce these enzymes and thus have become resistant to first line as well as "last defense" antimicrobials used in hospitals. Carbavance was designed to address Gram-negative bacteria that produce new beta-lactamase enzymes that have spread in the US and Europe, including strains producing the Klebsiella pneumoniae carbapenemase (KPC) enzyme.
"It is recognized that the worldwide spread of relatively common hospital pathogens producing multiple beta-lactamases, including the KPC enzyme, threatens a highly useful class of antimicrobial agents," said Dr. Michael N. Dudley, Senior VP for Research and Development and Chief Scientific Officer at Rempex. "Rempex and our scientific collaborators look forward to presenting the data on Carbavance that has supported initiation of human studies. We are working with clinical investigators and regulatory authorities on designing a development pathway that can speed the availability of this agent to patients and clinicians."
PR Newswire